AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.
Combining longitudinal claims data with deeper inpatient detail supports stronger real-world evidence for life sciences and medical device research.
Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.
GEBRO Holding and Spektus Pharma have agreed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice daily.
The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results